Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies

[1]  James D. Akula,et al.  The neural retina in retinopathy of prematurity , 2017, Progress in Retinal and Eye Research.

[2]  J. Rivera,et al.  Choroidal Involution Is Associated with a Progressive Degeneration of the Outer Retinal Function in a Model of Retinopathy of Prematurity: Early Role for IL-1β. , 2016, The American journal of pathology.

[3]  J. Rivera,et al.  Review of the mechanisms and therapeutic avenues for retinal and choroidal vascular dysfunctions in retinopathy of prematurity , 2016, Acta paediatrica.

[4]  M. K. Erol,et al.  CHOROIDAL THICKNESS IN INFANTS WITH RETINOPATHY OF PREMATURITY , 2016, Retina.

[5]  J. Skranes,et al.  Systemic endogenous erythropoietin and associated disorders in extremely preterm newborns , 2016, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[6]  F. Lefebvre,et al.  Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity , 2016, Pediatrics.

[7]  N. Campos,et al.  Evaluation of retinal , choroidal thickness and retinal pigmented epithelium using Cirrus SD-OCT in Portuguese children with history of preterm birth , 2016 .

[8]  S. Biswal,et al.  Nrf2 in ischemic neurons promotes retinal vascular regeneration through regulation of semaphorin 6A , 2015, Proceedings of the National Academy of Sciences.

[9]  O. Topolcan,et al.  The Measurement of Intraocular Biomarkers in Various Stages of Proliferative Diabetic Retinopathy Using Multiplex xMAP Technology , 2015, Journal of ophthalmology.

[10]  Junhao Hu,et al.  Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis , 2015, EMBO molecular medicine.

[11]  A. Haas,et al.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity , 2015, PloS one.

[12]  M. Klufas,et al.  Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years. , 2015, Journal of pediatric ophthalmology and strabismus.

[13]  A. Józkowicz,et al.  Cellular and molecular mechanisms of inflammation‐induced angiogenesis , 2015, IUBMB life.

[14]  A. Leviton,et al.  Systemic Inflammation in the Extremely Low Gestational Age Newborn Following Maternal Genitourinary Infections , 2015, American journal of reproductive immunology.

[15]  R. Hansen,et al.  Temporal summation in children with a history of retinopathy of prematurity. , 2015, Investigative ophthalmology & visual science.

[16]  M. Walsh,et al.  Causes and timing of death in extremely premature infants from 2000 through 2011. , 2015, The New England journal of medicine.

[17]  A. Trunov,et al.  Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy , 2015, Indian journal of ophthalmology.

[18]  A. Leviton,et al.  The relationship between TSH and systemic inflammation in extremely preterm newborns , 2015, Endocrine.

[19]  Abdelrahman Salman,et al.  Structural, Visual and Refractive Outcomes of Intravitreal Aflibercept Injection in High-Risk Prethreshold Type 1 Retinopathy of Prematurity , 2014, Ophthalmic Research.

[20]  T. O'Shea,et al.  Are preterm newborns who have relative hyperthyrotropinemia at increased risk of brain damage? , 2014, Journal of pediatric endocrinology & metabolism : JPEM.

[21]  A. Chuang,et al.  Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. , 2014, JAMA ophthalmology.

[22]  M F Anderson,et al.  Choroidal thickness in regressed retinopathy of prematurity , 2014, Eye.

[23]  Tao Li,et al.  Serum concentrations of cytokines in infants with retinopathy of prematurity , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[24]  A. Leviton,et al.  Endogenous erythropoietin varies significantly with inflammation-related proteins in extremely premature newborns. , 2014, Cytokine.

[25]  Y. Hwang,et al.  Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes , 2014, Eye.

[26]  P. Hüppi,et al.  Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. , 2014, JAMA.

[27]  Min Zhao,et al.  Placental growth factor expression is reversed by antivascular endothelial growth factor therapy under hypoxic conditions , 2014, World Journal of Pediatrics.

[28]  W. Carlo,et al.  Genetic variants associated with severe retinopathy of prematurity in extremely low birth weight infants. , 2014, Investigative ophthalmology & visual science.

[29]  J. Duker,et al.  Retinopathy of prematurity and brain damage in the very preterm newborn. , 2014, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[30]  H. Lee,et al.  Neonatal systemic inflammation in rats alters retinal vessel development and simulates pathologic features of retinopathy of prematurity , 2014, Journal of Neuroinflammation.

[31]  A. Ohlsson,et al.  Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. , 2014, The Cochrane database of systematic reviews.

[32]  I. Corsini,et al.  Early fresh‐frozen plasma transfusion decreases the risk of retinopathy of prematurity , 2014, Transfusion.

[33]  R. Ohls,et al.  Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates , 2014, Current opinion in pediatrics.

[34]  M. Wright,et al.  Transcriptome profiling of the newborn mouse brain after hypoxia–reoxygenation: hyperoxic reoxygenation induces inflammatory and energy failure responsive genes , 2014, Pediatric Research.

[35]  Deanne K. Thompson,et al.  Free Thyroxine Levels After Very Preterm Birth and Neurodevelopmental Outcomes at Age 7 Years , 2014, Pediatrics.

[36]  Sabita Roy,et al.  Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation , 2014, Journal of Neuroimmune Pharmacology.

[37]  P. Davis,et al.  Association between severe retinopathy of prematurity and nonvisual disabilities at age 5 years. , 2014, JAMA.

[38]  A. Barber,et al.  Regulation of fibroblast growth factor 2 expression in oxygen-induced retinopathy. , 2014, Investigative ophthalmology & visual science.

[39]  S. Chemtob,et al.  Systemic inflammation perturbs developmental retinal angiogenesis and neuroretinal function. , 2013, Investigative ophthalmology & visual science.

[40]  A. Fielder,et al.  Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010 , 2013, Pediatric Research.

[41]  Neil Marlow,et al.  Preterm birth–associated neurodevelopmental impairment estimates at regional and global levels for 2010 , 2013, Pediatric Research.

[42]  S. Tsirka,et al.  Monocyte chemoattractant protein-1 and the blood–brain barrier , 2013, Cellular and Molecular Life Sciences.

[43]  Lois E. H. Smith,et al.  WINROP Identifies Severe Retinopathy of Prematurity at an Early Stage in a Nation-Based Cohort of Extremely Preterm Infants , 2013, PloS one.

[44]  P. Hardy,et al.  Microglia and Interleukin-1&bgr; in Ischemic Retinopathy Elicit Microvascular Degeneration Through Neuronal Semaphorin-3A , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[45]  Yen-Po Chen,et al.  Choroidal thickness in patients with a history of retinopathy of prematurity. , 2013, JAMA ophthalmology.

[46]  Sina Farsiu,et al.  Choroid development and feasibility of choroidal imaging in the preterm and term infants utilizing SD-OCT. , 2013, Investigative ophthalmology & visual science.

[47]  K. Dobkins,et al.  Delayed luminance and chromatic contrast sensitivity in infants with spontaneously regressed retinopathy of prematurity , 2013, Documenta Ophthalmologica.

[48]  J. Jonas,et al.  Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. , 2013, American journal of ophthalmology.

[49]  G. Gole,et al.  Retinopathy of prematurity-incidence today. , 2013, Clinics in perinatology.

[50]  K. Park,et al.  The relationship between cord blood cytokine levels and perinatal factors and retinopathy of prematurity: a gestational age-matched case-control study. , 2013, Investigative ophthalmology & visual science.

[51]  G. Holmström,et al.  Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? , 2013, Acta ophthalmologica.

[52]  M. Bloch,et al.  Meta-analysis of LCPUFA Supplementation of Infant Formula and Visual Acuity , 2013, Pediatrics.

[53]  W. Fierson.  Screening Examination of Premature Infants for Retinopathy of Prematurity , 2013, Pediatrics.

[54]  K. Safranow,et al.  Potential contribution of mobilized circulating endothelial progenitor cells to development of retinal neovascularization in preterm infants with ROP. , 2013, Klinika oczna.

[55]  D. Maric,et al.  Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. , 2012, Blood.

[56]  M. Saint-Geniez,et al.  Expression and role of VEGF--a in the ciliary body. , 2012, Investigative ophthalmology & visual science.

[57]  E. Aguilar,et al.  Targeted deletion of Vegfa in adult mice induces vision loss. , 2012, The Journal of clinical investigation.

[58]  Kyung-Ah Park,et al.  Analysis of spectral-domain optical coherence tomography in preterm children: retinal layer thickness and choroidal thickness profiles. , 2012, Investigative ophthalmology & visual science.

[59]  S. Juul.  Neuroprotective role of erythropoietin in neonates , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[60]  A. Pandey,et al.  Insulin-Like Growth Factors Promote Vasculogenesis in Embryonic Stem Cells , 2012, PloS one.

[61]  O. Dammann,et al.  Perinatal infection, inflammation, and retinopathy of prematurity. , 2012, Seminars in fetal & neonatal medicine.

[62]  Anna L. Ells,et al.  Are we there yet? Bevacizumab therapy for retinopathy of prematurity , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[63]  J. Duker,et al.  Neonatal bacteremia and retinopathy of prematurity: the ELGAN study. , 2011, Archives of ophthalmology.

[64]  S. Faghihzadeh,et al.  Roles of IL-8 in Ocular Inflammations: A Review , 2011, Ocular immunology and inflammation.

[65]  J. Rivera,et al.  Understanding Retinopathy of Prematurity: Update on Pathogenesis , 2011, Neonatology.

[66]  H. Masuda,et al.  Aberrant kinetics of bone marrow-derived endothelial progenitor cells in the murine oxygen-induced retinopathy model. , 2011, Investigative ophthalmology & visual science.

[67]  P. Carmeliet,et al.  Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration. , 2011, Investigative ophthalmology & visual science.

[68]  H. Agostini,et al.  Activation of retinal microglia rather than microglial cell density correlates with retinal neovascularization in the mouse model of oxygen-induced retinopathy , 2011, Journal of Neuroinflammation.

[69]  D. Vanderveen,et al.  Placenta microbiology and histology and the risk for severe retinopathy of prematurity. , 2011, Investigative ophthalmology & visual science.

[70]  Pierre Lachapelle,et al.  Choroidal involution is a key component of oxygen-induced retinopathy. , 2011, Investigative ophthalmology & visual science.

[71]  H. Fledelius,et al.  Late subsequent ocular morbidity in retinopathy of prematurity patients, with emphasis on visual loss caused by insidious ‘involutive’ pathology: an observational series , 2011, Acta ophthalmologica.

[72]  C. Luu,et al.  Retinal ganglion cell death is induced by microglia derived pro‐inflammatory cytokines in the hypoxic neonatal retina , 2011, The Journal of pathology.

[73]  Akiyoshi Uemura,et al.  Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. , 2011, The Journal of clinical investigation.

[74]  Alan W. Stitt,et al.  Vascular stem cells and ischaemic retinopathies , 2011, Progress in Retinal and Eye Research.

[75]  Lois E. H. Smith,et al.  Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. , 2011, Blood.

[76]  R. Mortimer,et al.  Thyroid hormones and fetal neurological development. , 2011, The Journal of endocrinology.

[77]  R. C. Silveira,et al.  Assessment of the contribution of cytokine plasma levels to detect retinopathy of prematurity in very low birth weight infants. , 2011, Investigative ophthalmology & visual science.

[78]  Alice Z Chuang,et al.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. , 2011, The New England journal of medicine.

[79]  S. Kusaka,et al.  Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity. , 2011, American journal of ophthalmology.

[80]  A. Hellström,et al.  Screening for retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. , 2009, Archives of ophthalmology.

[81]  Alan W. Stitt,et al.  Outgrowth endothelial cells: characterization and their potential for reversing ischemic retinopathy. , 2010, Investigative ophthalmology & visual science.

[82]  D. Hougaard,et al.  Proliferative Retinopathy Is Associated with Impaired Increase in BDNF and RANTES Expression Levels after Preterm Birth , 2010, Neonatology.

[83]  M. Arcasoy.  Non-erythroid effects of erythropoietin , 2010, Haematologica.

[84]  D. Karczewicz,et al.  Circulating stem cell populations in preterm infants: implications for the development of retinopathy of prematurity. , 2010, Archives of ophthalmology.

[85]  J. Fiascone,et al.  Infection, Oxygen, and Immaturity: Interacting Risk Factors for Retinopathy of Prematurity , 2010, Neonatology.

[86]  G. Li,et al.  Redundant Mechanisms for Vascular Growth Factors in Retinopathy of Prematurity in vitro , 2010, Ophthalmic Research.

[87]  A. Neubauer,et al.  Erythropoietin improves neurodevelopmental outcome of extremely preterm infants , 2010, Annals of neurology.

[88]  L. Sirota,et al.  Outcome of Early-Onset Sepsis in a National Cohort of Very Low Birth Weight Infants , 2010, Pediatrics.

[89]  S. Shankaran,et al.  Perinatal Systemic Inflammatory Response Syndrome and Retinopathy of Prematurity , 2010, Pediatric Research.

[90]  Josh Wallman,et al.  The multifunctional choroid , 2010, Progress in Retinal and Eye Research.

[91]  R. Hansen,et al.  Long-term effects of retinopathy of prematurity (ROP) on rod and rod-driven function , 2011, Documenta Ophthalmologica.

[92]  G. Natarajan,et al.  Circulating β Chemokine and MMP 9 as Markers of Oxidative Injury in Extremely Low Birth Weight Infants , 2010, Pediatric Research.

[93]  B. Ambati,et al.  Mediators of ocular angiogenesis , 2009, Journal of Genetics.

[94]  Y. Hata,et al.  Comprehensive Analysis of Inflammatory Immune Mediators in Vitreoretinal Diseases , 2009, PloS one.

[95]  M. Hartnett,et al.  Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. , 2009, Experimental eye research.

[96]  T. Fujikado,et al.  Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. , 2009, Ophthalmology.

[97]  James D. Akula,et al.  The neurovascular retina in retinopathy of prematurity , 2009, Progress in Retinal and Eye Research.

[98]  J. Micieli,et al.  A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. , 2009, American journal of ophthalmology.

[99]  T. Fujikado,et al.  Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. , 2009, Ophthalmology.

[100]  E. Niki.  Lipid peroxidation: physiological levels and dual biological effects. , 2009, Free radical biology & medicine.

[101]  O. Dammann,et al.  Fetal Inflammatory Response and Brain Injury in the Preterm Newborn , 2009, Journal of child neurology.

[102]  E. Crivellato,et al.  Immune cells and angiogenesis , 2009, Journal of cellular and molecular medicine.

[103]  R. Rao,et al.  Brain-Derived Neurotrophic Factor in Infants <32 Weeks Gestational Age: Correlation With Antenatal Factors and Postnatal Outcomes , 2009, Pediatric Research.

[104]  E. Asztalos,et al.  Impact of neonatal thyroid hormone insufficiency and medical morbidity on infant neurodevelopment and attention following preterm birth. , 2009, Thyroid : official journal of the American Thyroid Association.

[105]  P. Carmeliet,et al.  Oxygen-Induced Retinopathy in Mice: Amplification by Neonatal IGF-I Deficit and Attenuation by IGF-I Administration , 2009, Pediatric Research.

[106]  V. Fellman,et al.  Fresh-frozen plasma as a source of exogenous insulin-like growth factor-I in the extremely preterm infant. , 2009, The Journal of clinical endocrinology and metabolism.

[107]  G. Holmström,et al.  Incidence of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. , 2009, Archives of ophthalmology.

[108]  T. O'Shea,et al.  Cytokines and perinatal brain damage. , 2008, Clinics in perinatology.

[109]  Magali Saint-Geniez,et al.  Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.

[110]  R. Apte,et al.  Interleukin-10 Promotes Pathological Angiogenesis by Regulating Macrophage Response to Hypoxia during Development , 2008, PloS one.

[111]  M. Trese,et al.  Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. , 2008, Ophthalmology.

[112]  T. Salt,et al.  Dendritic Pathology in the Superior Colliculus in a Rat Model of Experimental Glaucoma , 2008 .

[113]  J. Schulte‐Mönting,et al.  VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity , 2008, British Journal of Ophthalmology.

[114]  Lois E. H. Smith,et al.  Erythropoietin deficiency decreases vascular stability in mice. , 2008, The Journal of clinical investigation.

[115]  J. Y. Shin,et al.  Deguelin inhibits retinal neovascularization by down-regulation of HIF-1α in oxygen-induced retinopathy , 2008, Journal of cellular and molecular medicine.

[116]  M. Levene,et al.  Matrix Metalloproteinases and Their Tissue Inhibitors in Preterm Perinatal Complications , 2007, Reproductive Sciences.

[117]  G. Neufeld,et al.  Semaphorin-3A and Semaphorin-3F Work Together to Repel Endothelial Cells and to Inhibit Their Survival by Induction of Apoptosis* , 2007, Journal of Biological Chemistry.

[118]  David T. Shima,et al.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. , 2007, The American journal of pathology.

[119]  Lois E. H. Smith,et al.  Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.

[120]  A. Di Polo,et al.  Neuroprotection in the juvenile rat model of light-induced retinopathy: evidence suggesting a role for FGF-2 and CNTF. , 2007, Investigative ophthalmology & visual science.

[121]  V. Fellman,et al.  Inflammation at birth and the insulin‐like growth factor system in very preterm infants , 2007, Acta paediatrica.

[122]  E. Palmer,et al.  Severe visual impairment in children with mild or moderate retinal residua following regressed threshold retinopathy of prematurity. , 2007, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[123]  A. Kelly,et al.  Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. , 2007, Biochemical Society transactions.

[124]  W. Jelkmann.  Erythropoietin after a century of research: younger than ever , 2007, European journal of haematology.

[125]  R. Hunt,et al.  Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants. , 2007, The Cochrane database of systematic reviews.

[126]  Lois E. H. Smith,et al.  Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. , 2006, Archives of ophthalmology.

[127]  Michael I Dorrell,et al.  Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. , 2006, The Journal of clinical investigation.

[128]  N. Rahimi.  Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. , 2006, Experimental eye research.

[129]  Mikko Nikinmaa,et al.  Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. , 2006, Experimental eye research.

[130]  M. Leduc,et al.  Potential role of microglia in retinal blood vessel formation. , 2006, Investigative ophthalmology & visual science.

[131]  C. Mailhos,et al.  Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. , 2006, The American journal of pathology.

[132]  T. Dörk,et al.  Interleukin-10 High Producer Allele and Ultrasound-Defined Periventricular White Matter Abnormalities in Preterm Infants: A Preliminary Study , 2006, Neuropediatrics.

[133]  M. Msall.  The Retina as a Window to the Brain in Vulnerable Neonates , 2006, Pediatrics.

[134]  Lois E. H. Smith,et al.  Postnatal Head Growth Deficit Among Premature Infants Parallels Retinopathy of Prematurity and Insulin-like Growth Factor-1 Deficit , 2006, Pediatrics.

[135]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[136]  Section on Ophthalmology.  Screening examination of premature infants for retinopathy of prematurity. , 2001, Pediatrics.

[137]  A. Mccormick,et al.  Argon laser photocoagulation for retinopathy of prematurity: long-term outcome , 2005, Eye.

[138]  William V Good,et al.  The Incidence and Course of Retinopathy of Prematurity: Findings From the Early Treatment for Retinopathy of Prematurity Study , 2005, Pediatrics.

[139]  C. Palmer,et al.  Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell cultures , 2005, Journal of Neuroimmunology.

[140]  G. Quinn,et al.  Characteristics of Infants With Severe Retinopathy of Prematurity in Countries With Low, Moderate, and High Levels of Development: Implications for Screening Programs , 2005, Pediatrics.

[141]  Gary W. Williams,et al.  Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections. , 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[142]  M. R. Powers,et al.  Increased Expression of Chemokine KC, an Interleukin-8 Homologue, in a Model of Oxygen-Induced Retinopathy , 2005, Current eye research.

[143]  P. Hardy,et al.  Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy. , 2004, Free radical biology & medicine.

[144]  E. Palmer,et al.  Health-related quality of life at age 10 years in very low-birth-weight children with and without threshold retinopathy of prematurity. , 2004, Archives of ophthalmology.

[145]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[146]  A. Mccormick,et al.  39 Argon Laser Photocoagulation for Retinopathy of Prematurity: A Case Series of Long Term Outcome , 2004 .

[147]  R. Schulz,et al.  MMP-2 and MMP-9 and Their Tissue Inhibitors in the Plasma of Preterm and Term Neonates , 2004, Pediatric Research.

[148]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[149]  R. Hardy,et al.  Educational and social competencies at 8 years in children with threshold retinopathy of prematurity in the CRYO-ROP multicenter study. , 2004, Pediatrics.

[150]  Alan W. Stitt,et al.  Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. , 2004, The American journal of pathology.

[151]  S. Yoshida,et al.  Induction of IL-8, MCP-1, and bFGF by TNF-α in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[152]  Y. Pang,et al.  Maternal infection-induced white matter injury is reduced by treatment with interleukin-10. , 2003, American journal of obstetrics and gynecology.

[153]  W. Tasman,et al.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. , 2004, Archives of ophthalmology.

[154]  A. Fielder,et al.  Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial. , 2003, Archives of ophthalmology.

[155]  Lois E. H. Smith,et al.  Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. , 2003, Pediatrics.

[156]  A. Bikfalvi,et al.  Involvement of fibroblast growth factors in choroidal angiogenesis and retinal vascularization. , 2003, Experimental eye research.

[157]  A. Luttun,et al.  Placental growth factor and its receptor, vascular endothelial growth factor receptor‐1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders , 2003, Journal of thrombosis and haemostasis : JTH.

[158]  Y. Ogura,et al.  Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease , 2003, Nature Medicine.

[159]  Mark Batterbury,et al.  Ocular growth and refractive error development in premature infants without retinopathy of prematurity. , 2003, Investigative ophthalmology & visual science.

[160]  S. Yoshida,et al.  Role of MCP‐1 and MIP‐1α in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization , 2003, Journal of leukocyte biology.

[161]  J. Bennett,et al.  Gene therapy and animal models for retinal disease. , 2003, Developments in ophthalmology.

[162]  M. Matsumura,et al.  Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. , 2003, Investigative ophthalmology & visual science.

[163]  A. Bikfalvi,et al.  The role of fibroblast growth factors in vascular development. , 2002, Trends in molecular medicine.

[164]  J. Bennett,et al.  Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[165]  P. Schimmel,et al.  Bone marrow–derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis , 2002, Nature Medicine.

[166]  A. Luttun,et al.  Loss of placental growth factor protects mice against vascular permeability in pathological conditions. , 2002, Biochemical and biophysical research communications.

[167]  M. Pinazo-Durán,et al.  Low Thyroid Hormone Levels Impair the Perinatal Development of the Rat Retina , 2002, Ophthalmic Research.

[168]  Lois E. H. Smith,et al.  IGF-I is critical for normal vascularization of the human retina. , 2002, The Journal of clinical endocrinology and metabolism.

[169]  B. Fleck,et al.  Retinopathy of prematurity: causation. , 2001, Seminars in neonatology : SN.

[170]  H. Forman,et al.  Biphasic Effects of 15-Deoxy-&Dgr;12,14-Prostaglandin J2 on Glutathione Induction and Apoptosis in Human Endothelial Cells , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[171]  P. Campochiaro,et al.  Fibroblast growth factor-2 decreases hyperoxia-induced photoreceptor cell death in mice. , 2001, The American journal of pathology.

[172]  I. Chowers,et al.  Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity , 2001, The British journal of ophthalmology.

[173]  Lois E. H. Smith,et al.  Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[174]  N. Sharif,et al.  Pharmacology and autoradiography of human DP prostanoid receptors using [3H]‐BWA868C, a DP receptor‐selective antagonist radioligand , 2000, British journal of pharmacology.

[175]  E. Palmer,et al.  Severity of Neonatal Retinopathy of Prematurity Is Predictive of Neurodevelopmental Functional Outcome at Age 5.5 Years , 2000, Pediatrics.

[176]  P. Hardy,et al.  Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. , 2000, Cardiovascular research.

[177]  S. Opal,et al.  Anti-inflammatory cytokines. , 2000, Chest.

[178]  S. Molotchnikoff,et al.  Regulation of endothelial nitric oxide synthase by PGD(2) in the developing choroid. , 2000, American journal of physiology. Heart and circulatory physiology.

[179]  Lois E. H. Smith,et al.  Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor , 1999, Nature Medicine.

[180]  S. Juul,et al.  Why Is Erythropoietin Present in Human Milk? Studies of Erythropoietin Receptors on Enterocytes of Human and Rat Neonates , 1999, Pediatric Research.

[181]  Alan W. Stitt,et al.  Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. , 1999, Biochemical and biophysical research communications.

[182]  M. Elmlinger,et al.  Limited Proteolysis of the IGF Binding Protein-2 (IGFBP-2) by a Specific Serine Protease Activity in Early Breast Milk , 1999, Pediatric Research.

[183]  D. Gilroy,et al.  Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.

[184]  A. Das,et al.  Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. , 1999, Archives of ophthalmology.

[185]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[186]  P. Campochiaro,et al.  Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. , 1998, The American journal of pathology.

[187]  J. Isner,et al.  Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. , 1998, Circulation research.

[188]  G. Holmström,et al.  Neonatal risk factors for retinopathy of prematurity--a population-based study. , 1998, Acta ophthalmologica Scandinavica.

[189]  Wm Fierson,et al.  Screening examination of premature infants for retinopathy of prematurity. A joint statement of the American Academy of Pediatrics, the American Association for Pediatric Ophthalmology and Strabismus, and the American Academy of Ophthalmology. , 2013, Pediatrics.

[190]  M. Salvat-Serra,et al.  Risk factors in retinopathy of prematurity , 1997 .

[191]  E. Doménech,et al.  Breast-feeding and growth factors in preterm newborn infants. , 1997, Journal of pediatric gastroenterology and nutrition.

[192]  P. Hardy,et al.  Increased nitric oxide synthesis and action preclude choroidal vasoconstriction to hyperoxia in newborn pigs. , 1996, Circulation research.

[193]  P. Hardy,et al.  Nitric Oxide in Retinal and Choroidal Blood Flow Autoregulation in Newborn Pigs: Interactions with Prostaglandins , 1996, Pediatric Research.

[194]  S. Fliesler,et al.  Chemistry and metabolism of lipids in the vertebrate retina. , 1983, Progress in lipid research.

[195]  B. Kushner,et al.  Retrolental Fibroplasia. II. Pathologic correlation. , 1977, Archives of ophthalmology.

[196]  A. Garner,et al.  Vaso-obliteration and retrolental fibroplasia. , 1971, Proceedings of the Royal Society of Medicine.